Armored CAR T-cells: Utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy

Biochemical Society Transactions

Volumn 44, Issue 2, 2016, Pages 412-418

  Yeku, Oladapo O ^a   Brentjens, Renier J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adoptive immunotherapy; Armored chimaeric antigen receptor T cell (CAR T cell); Chimaeric antigen receptor

Indexed keywords

CD137 LIGAND; CD40 LIGAND; CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 12; AUTACOID; CYTOKINE; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; DENDRITIC CELL; DNA MODIFICATION; GENETIC ENGINEERING; HUMAN; LYMPHOCYTE FUNCTION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; IMMUNOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; LIGANDS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 85009895128     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20150291     Document Type: Review

References (53)

1. Davila, M.L., Bouhassira, D.C.G., Park, J.H., Curran, K.J., Smith, E.L., Pegram, H.J. and Brentjens, R. (2014) Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int. J. Hematol. 99, 361-371
2. Sadelain, M., Brentjens, R. and Rivière, I. (2013) The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388-398
3. Brentjens, R.J., Latouche, J.-B., Santos, E., Marti, F., Gong, M.C., Lyddane, C., King, P.D., Larson, S., Weiss, M., Rivière, I. et al. (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279-286
4. Stancovski, I., Schindler, D.G., Waks, T., Yarden, Y., Sela, M. and Eshhar, Z. (1993) Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151, 6577-6582
5. Lamers, C.H.J., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R. and Gratama, J.W. (2011) Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117, 72-82
6. Lamers, C.H.J., Sleijfer, S., Vulto, A.G., Kruit, W.H.J., Kliffen, M., Debets, R., Gratama, J.W., Stoter, G. and Oosterwijk, E. (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22
7. Till, B.G., Jensen, M.C., Wang, J., Chen, E.Y., Wood, B.L., Greisman, H.A., Qian, X., James, S.E., Raubitschek, A., Forman, S.J. et al. (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271
8. Chambers, C.A. and Allison, J.P. (1997) Co-stimulation in T cell responses. Curr. Opin. Immunol. 9, 396-404
9. Brentjens, R.J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintas-Cardama, A., Larson, S.M. and Sadelain, M. (2007) Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 5426-5435
10. Maher, J., Brentjens, R.J., Gunset, G., Rivière, I. and Sadelain, M. (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 20, 70-75
11. Savoldo, B., Ramos, C.A., Liu, E., Mims, M.P., Keating, M.J., Carrum, G., Kamble, R.T., Bollard, C.M., Gee, A.P., Mei, Z. et al. (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826
12. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M. et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38
13. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M. et al. (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25
14. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A. and June, C.H. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73
15. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. and June, C.H. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733
16. Zhao, Y., Wang, Q.J., Yang, S., Kochenderfer, J.N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S.A. and Morgan, R.A. (2009) A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563-5574
17. Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I. and Sadelain, M. (2010) Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18, 413-420
18. Wilkie, S., Picco, G., Foster, J., Davies, D.M., Julien, S., Cooper, L., Arif, S., Mather, S.J., Taylor-Papadimitriou, J., Burchell, J.M. et al. (2008) Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 180, 4901-4909
19. Pegram, H.J., Smith, E.L., Rafiq, S. and Brentjens, R.J. (2015) CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies? Immunotherapy 7, 545-561
20. Carra, G., Gerosa, F. and Trinchieri, G. (2000) Biosynthesis and posttranslational regulation of human IL-12. J. Immunol. 164, 4752-4761
21. Kerkar, S.P., Goldszmid, R.S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R.N., Leonardi, A.J., Morgan, R.A., Wang, E., Marincola, F.M. et al. (2011) IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746-4757
22. Zhao, J., Zhao, J. and Perlman, S. (2012) Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R. PLoS One 7, e46241
23. Addison, C.L., Bramson, J.L., Hitt, M.M., Muller, W.J., Gauldie, J. and Graham, F.L. (1998) Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther. 5, 1400-1409
24. Bramson, J.L., Hitt, M., Addison, C.L., Muller, W.J., Gauldie, J. and Graham, F.L. (1996) Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12 4937. Hum. Gene Ther. 16, 1995-2002
25. Hu, J., Yuan, X., Belladonna, M.L., Ong, J.M., Wachsmann-Hogiu, S., Farkas, D.L., Black, K.L. and Yu, J.S. (2006) Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 66, 8887-8896
26. Pegram, H.J., Lee, J.C., Hayman, E.G., Imperato, G.H., Tedder, T.F., Sadelain, M. and Brentjens, R.J. (2012) Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133-4141
27. Kerkar, S.P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D.C., Reger, R.N., Borman, Z.A., Zhang, L. et al. (2010) Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70, 6725-6734
28. Leonard, J.P., Sherman, M.L., Fisher, G.L., Buchanan, L.J., Larsen, G., Atkins, M.B., Sosman, J.A., Dutcher, J.P., Vogelzang, N.J. and Ryan, J.L. (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541-2548
29. Koneru, M., Purdon, T.J., Spriggs, D., Koneru, S. and Brentjens, R.J. (2015) IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 4, e994446
30. Koneru, M., O'Cearbhaill, R., Pendharkar, S., Spriggs, D.R. and Brentjens, R.J. (2015) A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 13, 102
31. Armitage, R.J., Fanslow, W.C., Strockbine, L., Sato, T.A., Clifford, K.N., Macduff, B.M., Anderson, D.M., Gimpel, S.D., Davis-Smith, T. and Maliszewski, C.R. (1992) Molecular and biological characterization of a murine ligand for CD40. Nature 357, 80-82
32. Schönbeck, U. and Libby, P. (2001) The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 58, 40-43
33. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A. and Alber, G. (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184, 747-752
34. Grewal, I.S., Xu, J. and Flavell, R.A. (1995) Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 378, 617-620
35. Bourgeois, C., Rocha, B. and Tanchot, C. (2002) A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297, 2060-2063
36. Curran, K.J., Seinstra, B.A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D.G., Purdon, T., Pegram, H.J. and Brentjens, R.J. (2015) Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol. Ther. 23, 769-778
37. Khong, A., Nelson, D.J., Nowak, A.K., Lake, R.A. and Robinson, B.W.S. (2012) The use of agonistic anti-CD40 therapy in treatments for cancer. Int. Rev. Immunol. 31, 246-266
38. Wierda, W.G., Cantwell, M.J., Woods, S.J., Rassenti, L.Z., Prussak, C.E. and Kipps, T.J. (2000) CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96, 2917-2924
39. Mangsbo, S.M., Broos, S., Fletcher, E., Veitonmäki, N., Furebring, C., Dahlén, E., Norlén, P., Lindstedt, M., Tötterman, T.H. and Ellmark, P. (2015) The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Clin. Cancer Res. 21, 1115-1126
40. Khalil, M. and Vonderheide, RH. (2007) Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther. 2, 61-65
41. Croft, M. (2009) The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9, 271-285
42. Watts, T.H. and DeBenedette, M.A. (1999) T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11, 286-293
43. DeBenedette, M.A., Shahinian, A., Mak, T.W. and Watts, T.H. (1997) Costimulation of CD28-T lymphocytes by 4-1BB ligand. J. Immunol. 158, 551-559
44. Wang, Q., Zhang, P., Zhang, Q., Wang, X., Li, J., Ma, C., Sun, W. and Zhang, L. (2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat. Med. J. 49, 192-200
45. Takahashi, C., Mittler, R.S. and Vella, A.T. (1999) Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162, 5037-5040
46. Sabbagh, L., Snell, L.M. and Watts, T.H. (2007) TNF family ligands define niches for T cell memory. Trends Immunol. 28, 333-339
47. Futagawa, T., Akiba, H., Kodama, T., Takeda, K., Hosoda, Y., Yagita, H. and Okumura, K. (2002) Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 14, 275-286
48. Stephan, M.T., Ponomarev, V., Brentjens, R.J., Chang, A.H., Dobrenkov, K.V., Heller, G. and Sadelain, M. (2007) T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13, 1440-1449
49. Zhao, Z., Condomines, M., van der Stegen, S.J.C., Perna, F., Kloss, C.C., Gunset, G., Plotkin, J. and Sadelain, M. (2015) Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415-428
50. Srivastava, S., Koch, M.A., Pepper, M. and Campbell, D.J. (2014) Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J. Exp. Med. 211, 961-974
51. Yang, X., Zhang, X., Fu, M.L., Weichselbaum, R.R., Gajewski, T.F., Guo, Y. and Fu, Y.-X. (2014) Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 25, 37-48
52. Spaapen, R.M., Leung, M.Y.K., Fuertes, M.B., Kline, J.P., Zhang, L., Zheng, Y., Fu, Y.-X., Luo, X., Cohen, K.S. and Gajewski, T.F. (2014) Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature. J. Immunol. 193, 4254-4260
53. Hsu, C., Hughes, M.S., Zheng, Z., Bray, R.B., Rosenberg, S.A. and Morgan, R.A. (2005) Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J. Immunol. 175, 7226-7234